...
search icon
eq-img

Equillium Inc, Common Stock

EQ

NAQ

$0.4

-$0.01

(-2.46%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$13.76M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
48.64K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.06
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.34 L
$1.53 H
$0.4

About Equillium Inc, Common Stock

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameEQSectorS&P500
1-Week Return3.82%-3.24%-2.29%
1-Month Return-12.66%-5.96%5.13%
3-Month Return-47.6%-11.47%-1.04%
6-Month Return-48.05%-11.3%-3.3%
1-Year Return-72.6%-8.64%9.3%
3-Year Return-83.94%-2.75%39.44%
5-Year Return-88.65%29.73%90.79%
10-Year Return-97.14%73.6%173.11%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue--15.76M36.08M41.09M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":38.35,"profit":true},{"date":"2023-12-31","value":87.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue45.00K72.00K118.00K126.00K137.00K[{"date":"2020-12-31","value":32.85,"profit":true},{"date":"2021-12-31","value":52.55,"profit":true},{"date":"2022-12-31","value":86.13,"profit":true},{"date":"2023-12-31","value":91.97,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(45.00K)(72.00K)15.64M35.96M40.96M[{"date":"2020-12-31","value":-0.11,"profit":false},{"date":"2021-12-31","value":-0.18,"profit":false},{"date":"2022-12-31","value":38.19,"profit":true},{"date":"2023-12-31","value":87.79,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)(Infinity%)99.25%99.65%99.67%[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":99.58,"profit":true},{"date":"2023-12-31","value":99.98,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses29.55M37.79M54.79M50.61M49.36M[{"date":"2020-12-31","value":53.93,"profit":true},{"date":"2021-12-31","value":68.97,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.37,"profit":true},{"date":"2024-12-31","value":90.1,"profit":true}]
Operating Income(29.55M)(37.79M)(62.08M)(14.52M)(8.27M)[{"date":"2020-12-31","value":-2954800000,"profit":false},{"date":"2021-12-31","value":-3778600000,"profit":false},{"date":"2022-12-31","value":-6207600000,"profit":false},{"date":"2023-12-31","value":-1452200000,"profit":false},{"date":"2024-12-31","value":-826900000,"profit":false}]
Total Non-Operating Income/Expense(888.00K)(2.28M)(985.00K)3.02M1.94M[{"date":"2020-12-31","value":-29.37,"profit":false},{"date":"2021-12-31","value":-75.49,"profit":false},{"date":"2022-12-31","value":-32.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":64.31,"profit":true}]
Pre-Tax Income(29.81M)(39.05M)(62.43M)(12.76M)(7.71M)[{"date":"2020-12-31","value":-2981300000,"profit":false},{"date":"2021-12-31","value":-3905200000,"profit":false},{"date":"2022-12-31","value":-6242800000,"profit":false},{"date":"2023-12-31","value":-1275500000,"profit":false},{"date":"2024-12-31","value":-770600000,"profit":false}]
Income Taxes(45.00K)(72.00K)45.28M580.00K361.00K[{"date":"2020-12-31","value":-0.1,"profit":false},{"date":"2021-12-31","value":-0.16,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":1.28,"profit":true},{"date":"2024-12-31","value":0.8,"profit":true}]
Income After Taxes(29.77M)(38.98M)(107.71M)(13.34M)(8.07M)[{"date":"2020-12-31","value":-2976800000,"profit":false},{"date":"2021-12-31","value":-3898000000,"profit":false},{"date":"2022-12-31","value":-10770700000,"profit":false},{"date":"2023-12-31","value":-1333500000,"profit":false},{"date":"2024-12-31","value":-806700000,"profit":false}]
Income From Continuous Operations(29.81M)(39.11M)(62.43M)(8.22M)(8.07M)[{"date":"2020-12-31","value":-2981300000,"profit":false},{"date":"2021-12-31","value":-3911100000,"profit":false},{"date":"2022-12-31","value":-6242800000,"profit":false},{"date":"2023-12-31","value":-822000000,"profit":false},{"date":"2024-12-31","value":-806700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(29.77M)(38.98M)(107.71M)(13.34M)(8.07M)[{"date":"2020-12-31","value":-2976800000,"profit":false},{"date":"2021-12-31","value":-3898000000,"profit":false},{"date":"2022-12-31","value":-10770700000,"profit":false},{"date":"2023-12-31","value":-1333500000,"profit":false},{"date":"2024-12-31","value":-806700000,"profit":false}]
EPS (Diluted)(1.49)(1.35)(1.18)(0.39)(0.23)[{"date":"2020-12-31","value":-149,"profit":false},{"date":"2021-12-31","value":-135,"profit":false},{"date":"2022-12-31","value":-118,"profit":false},{"date":"2023-12-31","value":-39,"profit":false},{"date":"2024-12-31","value":-23.02,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

EQ
Cash Ratio 2.42
Current Ratio 2.70

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

EQ
ROA (LTM) -29.73%
ROE (LTM) -88.32%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

EQ
Debt Ratio Lower is generally better. Negative is bad. 0.37
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.63

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

EQ
Trailing PE NM
Forward PE 1.53
P/S (TTM) 0.48
P/B 1.37
Price/FCF NM
EV/R 0.01
EV/Ebitda 0.07

FAQs

What is Equillium Inc share price today?

Equillium Inc (EQ) share price today is $0.4

Can Indians buy Equillium Inc shares?

Yes, Indians can buy shares of Equillium Inc (EQ) on Vested. To buy Equillium Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EQ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Equillium Inc be purchased?

Yes, you can purchase fractional shares of Equillium Inc (EQ) via the Vested app. You can start investing in Equillium Inc (EQ) with a minimum investment of $1.

How to invest in Equillium Inc shares from India?

You can invest in shares of Equillium Inc (EQ) via Vested in three simple steps:

  • Click on Sign Up or Invest in EQ stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Equillium Inc shares
What is Equillium Inc 52-week high and low stock price?

The 52-week high price of Equillium Inc (EQ) is $1.53. The 52-week low price of Equillium Inc (EQ) is $0.34.

What is Equillium Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Equillium Inc (EQ) is 1.37

What is the Market Cap of Equillium Inc?

The market capitalization of Equillium Inc (EQ) is $13.76M

What is Equillium Inc’s stock symbol?

The stock symbol (or ticker) of Equillium Inc is EQ

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top